Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, multicenter, dose escalation study of CAT-8015 in patients with relapse or refractory chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL).

Next Previous
X
Search
Trial Profile

A phase 1, multicenter, dose escalation study of CAT-8015 in patients with relapse or refractory chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL).

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Lymphoid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Cambridge Antibody Technology; MedImmune

    • Most Recent Events

    • 04 Jun 2019 Results assessing pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jan 2012 Actual patient number is 11 as reported by ClinicalTrials.gov (NCT00587457).
    • 04 Jan 2012 Actual patient number is 11 as reported by ClinicalTrials.gov (NCT00587457).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top